Pencil Biosciences

Pencil Biosciences

Private
MacclesfieldHealthcare & Life Scienceshttps://www.pencilbiosciences.com/

Last Round

Grant

Apr 23, 2025

Total Funding Raised

$7.76M

Company Overview

Pencil Biosciences is a biotechnology company that is developing a synthetic, non-CRISPR gene editing platform for utilization in genomic medicine, cell and gene therapies, and bioproduction.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

non-CRISPR gene editinggene editing platformCRISPR alternativegene modulationRNA-guided systemcell and gene therapyCGTrare disease therapygenetic disease therapysynthetic gene editingbiotech licensinggenomic medicinecancer therapycell line engineeringbiopharma partnershipsbioproduction

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pencil Biosciences Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Pencil Biosciences Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantApr 23, 2025
SeedSep 28, 2023
SeedFeb 15, 2020

Key People

Founding team and executive leadership

Amanda Smith

Chief Executive Officer

Executive Team

Pencil Biosciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2025

    $929K grant round completed.

  • May 8, 2024

    Grew 25% QoQ, from 12 to 15 employees.

Pencil Biosciences Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pencil Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pencil Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersMacclesfield
Employee Range17
Year Founded2018
Last FundingApr 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.